EXAONE Expert AI: Materials and New Drug Diagram

Strengths

• Proprietary training and validation data from the group's internal chemical and biological scenarios
• Expert AI positioning avoids head-on competition with general-purpose models

Weaknesses

• Limited market size in Korea, and weaker overseas brand recognition than US models
• Commercial revenue scale is still small, relying on parent company funding

Opportunities

• Global manufacturing companies are seeking vertical scientific AI as an alternative to general-purpose models
• Countries are promoting sovereign AI and local models, giving Korean models a policy window

Threats

• Giants such as OpenAI and Google are also entering the scientific discovery track
• Open-source models catching up in performance is compressing licensing pricing space